Journavx: How a New Non-Opioid Painkiller Is Opening a Different Route to Relief

For generations, the standard response to severe short-term pain has often involved an opioid. These medicines can be effective, but they also bring risks that have reshaped American medicine: sedation, respiratory depression, constipation, dependence and the possibility of misuse.

In January 2025, the U.S. Food and Drug Administration approved a different kind of prescription painkiller. Sold under the brand name Journavx, suzetrigine is intended for adults with moderate to severe acute pain. It does not belong to the opioid family, and it works through a pain pathway that researchers have been studying for years but had not previously been able to target with an approved drug.

The approval is not a promise that one medicine will replace opioids, nor does it settle the larger question of how acute pain should be treated. But it does mark a meaningful change in the menu available to clinicians. For the first time, doctors have an FDA-approved non-opioid medicine designed specifically to block pain signals before they reach the brain’s central processing systems.

A different place to interrupt pain

Suzetrigine targets a protein called NaV1.8. This sodium channel is found in peripheral pain-sensing neurons, the nerve cells that detect potentially damaging heat, pressure or tissue injury and begin sending electrical signals toward the spinal cord and brain.

When tissue is injured—for example, during surgery—these nerves can become unusually active. Their signals are part of the body’s warning system, but they are also what a patient experiences as pain. By selectively inhibiting NaV1.8, suzetrigine reduces the ability of those peripheral neurons to transmit pain signals.

That mechanism is different from the one used by opioids. Opioids act on receptors in the central nervous system and can alter both the experience of pain and the brain’s response to it. Suzetrigine was designed to work farther out in the nervous system, at the site where pain signals begin. For related reading, see NASA’s Deep-Space Laser Link Is Opening a Faster Way to Talk Across the Solar System.

The distinction matters because a medicine can be useful without reproducing every risk associated with opioid drugs. The FDA did not classify Journavx as a controlled substance. At the same time, the approval does not mean the drug is risk-free, and it does not establish that taking it will prevent opioid addiction or eliminate the need for opioids after every operation.

What the clinical trials showed

The FDA’s approval rested on two randomized, double-blind clinical trials involving adults with acute pain after surgery. One study followed people recovering from abdominoplasty, commonly called a tummy tuck. The other involved patients who had undergone bunion surgery.

Participants received either suzetrigine, a placebo or a commonly used opioid-and-acetaminophen combination. Researchers measured pain over the first 48 hours using a standard total pain-intensity score, while also allowing rescue medication when needed.

In both trials, suzetrigine reduced pain more than placebo. The studies also found that its pain-relieving effect was statistically comparable to the hydrocodone-acetaminophen comparator under the trial conditions. That is an important result, but it should be read narrowly: the trials examined specific postoperative settings, not every form of acute pain encountered in emergency departments, dental offices, sports medicine or home care.

The evidence also came from a carefully monitored research environment. Patients were selected according to study criteria, received scheduled doses and were observed by clinical teams. Real-world use will involve people with different ages, medical histories, medications and expectations.

The practical promise—and the limits

Journavx is approved for acute pain in adults, not for chronic pain. Acute pain usually refers to pain that begins suddenly and is linked to an injury, illness, procedure or operation. Chronic pain is a different medical problem, often involving changes in the nervous system that persist long after an initial injury has healed.

The approved dosing regimen begins with a 100-milligram loading dose, followed by 50 milligrams every 12 hours. The FDA’s prescribing information also sets a maximum treatment duration of 14 days. Those limits reflect the evidence available at approval and the fact that longer-term use has not been established in the same way. For related reading, see Congestion Pricing: How New York Turned Midtown Into a Different Kind of Everyday Place.

The drug is not intended to be mixed casually with every other medication. Suzetrigine is affected by enzymes in the liver, particularly the CYP3A system. Strong CYP3A inhibitors can raise the amount of drug in the body, while some other medicines may reduce its exposure. The FDA warning information also addresses interactions with hormonal contraceptives, because suzetrigine may reduce the effectiveness of certain contraceptive products.

In clinical studies, reported side effects included muscle spasms, skin rash and increased levels of creatine phosphokinase, an enzyme associated with muscle injury. As with any newly approved treatment, broader use will give doctors and regulators more information about uncommon reactions and how the drug performs in people who were underrepresented in trials.

Why this matters in the opioid era

Acute pain creates a difficult balancing act. Undertreated pain can delay movement and recovery, interfere with sleep and contribute to a patient’s distress. Opioids can provide strong relief, but prescribing them also requires attention to dose, duration, interactions, leftover pills and the possibility of dependence.

For clinicians, an additional non-opioid option could make combination treatment more flexible. A doctor might use a medicine such as suzetrigine alongside other non-opioid approaches, reserving an opioid for situations in which the overall pain burden requires it. Or, depending on the procedure and the patient, the new medicine might help reduce the amount of opioid needed.

That possibility remains a question for practice rather than a conclusion already proven by the approval trials. The studies showed that suzetrigine can relieve certain kinds of postoperative pain. They did not show that it will lower opioid prescribing across the health system, prevent opioid use disorder or work equally well for every patient.

Cost and access will matter too. A new branded medicine enters a healthcare system where older generic drugs are familiar and inexpensive. Whether hospitals, insurers and patients adopt Journavx widely will depend not only on its biology but also on coverage, availability, prescribing habits and how its benefits compare with existing combinations of medicines. For related reading, see The Grand Canalscape: How Phoenix Turned an Old Waterway Into an Everyday Route.

A long scientific road to one approval

The drug’s development reflects a broader effort to understand pain at the level of specific nerve channels. Scientists had identified NaV1.8 as an attractive target because it is concentrated in peripheral pain-sensing neurons. The challenge was to create a molecule that could block the target effectively without disrupting related sodium channels needed for normal nerve and heart function.

That kind of selectivity is difficult. Sodium channels help conduct electrical signals throughout the body, so an imprecise drug could cause serious problems. The clinical development of suzetrigine represents a step toward separating the electrical machinery involved in pain from the systems that control movement, sensation and vital functions.

It also illustrates how progress in medicine is often incremental. Journavx is not a universal anesthetic, a treatment for every painful condition or a replacement for careful diagnosis. Its importance lies in adding another scientifically distinct tool to a field that has relied heavily on a relatively small number of drug classes.

What comes next

The next test will happen outside the controlled conditions of clinical trials. Researchers and clinicians will need to learn how suzetrigine performs across different operations, injuries and patient populations. They will also watch for rare adverse events, real-world medication interactions and patterns of use that were difficult to capture before approval.

For patients, the most useful change may be a more informed conversation before a procedure: What kind of pain is expected? Which non-opioid treatments are reasonable? When would an opioid still be appropriate? What other medicines could interact with the prescription?

Those questions will not disappear with a new drug. But they can now include an option that reaches pain through a different route. In a country still dealing with the consequences of opioid exposure, that is more than a new brand name. It is evidence that the search for safer ways to control pain can produce practical results.